New combo aims to outsmart Drug-Resistant lung cancer
NCT ID NCT05845671
First seen Jan 16, 2026 · Last updated May 23, 2026 · Updated 21 times
Summary
This early-phase study tests a new drug, amivantamab, combined with standard targeted therapies (TKIs) in 12 adults with advanced non-small cell lung cancer that has specific gene changes (ALK, ROS1, or RET). The goal is to see if the combination can overcome resistance that often develops to TKIs alone. The study focuses on finding the safest dose and checking if tumors shrink.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
City of Hope Cancer Center
Duarte, California, 91010, United States
-
Outpatient CTRC
Aurora, Colorado, 80045, United States
-
University of Colorado Hospital
Aurora, Colorado, 80045, United States
-
University of Michigan Rogel Cancer Center
Ann Arbor, Michigan, 48109, United States
Conditions
Explore the condition pages connected to this study.